Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

Journal of Clinical Oncology

Volumn 24, Issue 12, 2006, Pages 1831-1838

  Hurley, Judith ^a   Doliny, Philomena ^b   Reis, Isildinha ^b   Silva, Orlando ^b   Gomez Fernandez, Carmen ^b   Velez, Pedro ^b   Pauletti, Giovanni ^b   Pegram, Mark D ^b   Slamon, Dennis J ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GOSERELIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANXIETY; ARTICLE; ASTHENIA; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERNATREMIA; HYPERTENSION; HYPOMAGNESEMIA; INDIGESTION; INFECTION; KIDNEY FAILURE; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PAIN; PRIORITY JOURNAL; RASH; SIDE EFFECT; SYSTEMIC THERAPY; THORAX PAIN; TINNITUS; TOOTH ABSCESS; TREATMENT RESPONSE; TUMOR VOLUME; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION; BREAST TUMOR; CLINICAL TRIAL; DISEASE COURSE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 33646376727     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.8886     Document Type: Article

References (41)

1. Schwartsmann G: Breast cancer in South America: Challenges to improve early detection and medical management of a public health problem. J Clin Oncol 19:118S-124S, 2001 (suppl 18)
2. Adebamowo CA, Adekunle OO: Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria. Br J Surg 86:665-668, 1999
3. National Cancer Data Base: Site by stage distribution of cases reported to the NCDB: Diagnosis year 2001. https://web.facs.org/ncdbr/help_compare6/ ver6_site_stage_2001.htm
4. Kaufmann M, von Minckwitz G, Smith R, et al: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 21:2600-2608, 2003
5. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003
6. Buzdar AU, Singletary SE, Theriault RL, et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412-3417, 1999
7. Penault-Llorca F, Sastre X, Fiche M, et al: Pathological response to neoadjuvant chemotherapy (CT): Final results of a prospective randomized trial of 4AT vs 4AC as induction therapy in patients with operable breast cancer using Sataloff classification. Breast Cancer Res Treat 57:67, 1999 (abstr 248)
8. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466, 2002
9. Untch M, Konecny G, Ditsch N, et al: Dosedense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: Results of a randomised AGO study. Proc Am Soc Clin Oncol 21:34a, 2002 (abstr 133)
10. von Minckwitz G, Costa SD, Raab G, et al: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. J Clin Oncol 19:3506-3515, 2001
11. von Minckwitz G, Raab G, Caputo A, et al: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685, 2005
12. Morrell LE, Lee YJ, Hurley J, et al: A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer 82:503-511, 1998
13. Jekunen AP, Christen RD, Shalinsky DR, et al: Synergistic interaction between cisplatin and Taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69:299-306, 1994
14. Kano Y, Akutsu M, Tsunoda S, et al: In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cancer Chemother Pharmacol 37:525-530, 1996
15. Engblom P, Rantanen V, Kulmala J, et al: Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br J Cancer 79:286-292, 1999
16. Alberti AM: A phase II study of docetaxel (T) and carboplatin (CBP) as second line chemotherapy in metastatic breast cancer. Proc Am Soc Clin Oncol 19:113a, 2000 (abstr 438)
17. Brufsky AM, Cleary D, Fuchs C, et al: First-line chemotherapy for metastatic breast cancer (MBC) with docetaxel (T), carboplatin (C), and trastuzumab (H) (TCH): A phase II trial. Proc Am Soc Clin Oncol 22:18, 2003 (abstr 71)
18. Lee YJ, Doliny P, Gomez-Fernandez C, et al: Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. Clin Breast Cancer 5:371-376, 2004
19. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Onccl 20:719-726, 2002
20. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
21. Slamon D, Pegram M: Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28:13-19, 2001
22. Pegram MD, Pienkowski T, Northfelt DW, et al: Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96:759-769, 2004
23. Robert NJ, Leyland-Jones B, Asmar L, et al: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. J Clin Oncol 22:20s, 2004 (suppl; abstr 573)
24. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628-3636, 2002
25. Pauletti G, Godolphin W, Press MF, et al: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72, 1996
26. Pauletti G, Dandekar S, Rong H, et al: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664, 2000
27. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
28. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
29. Collett D: Modelling Survival Data in Medical Research (ed 2). New York, NY, CRC Press, 2003
30. Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-102, 2001
31. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
32. Mass RD, Press M, Anderson S, et al: Improved survival benefit from herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol 20:22a, 2001 (abstr 85)
33. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer: International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056, 1992
34. Thor AD, Berry DA, Budman DR, et al: ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998
35. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685, 2005
36. Burstein HJ, Harris LN, Gelman R, et al: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 21:46-53, 2003
37. Harris LN, Burstein HJ, Gelman R, et al: Preoperative trastuzumab and vinorelbine (HN) is a highly active, well-tolerated regimen for HER2 3+/FISH+ stage II/III breast cancer. Proc Am Soc Clin Oncol 22:22, 2003 (abstr 86)
38. Bines J, Murad A, Lago S, et al: Multicenter Brazilian study of weekly docetaxel and trastuzumab as primary therapy in stage III, HER-2 overexpressing breast cancer. Proc Am Soc Clin Oncol 22:67, 2003 (abstr 268)
39. Schiffhauer LM, Griggs JJ, Ahrendt GM, et al: Docetaxel and trastuzumab as primary systemic therapy for HER-2/neu-overexpressing breast cancer. Proc Am Soc Clin Oncol 22:242, 2003 (abstr 969)
40. Van Pelt AE, Mohsin S, Elledge RM, et al: Neoadjuvant trastuzumab and docetaxel in breast cancer: Preliminary results. Clin Breast Cancer 4:348-353, 2003
41. Mohsin SK, Weiss HL, Gutierrez MC, et al: Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23:2460-2468, 2005